bluebird unveils $2.8m price for gene therapy Zynteglo on FDA approval
pharmaphorum
AUGUST 18, 2022
million price tag attached to the therapy when it was first made available in Europe, and is also well above the proposed $2.1 million level that cost-effectiveness organisation ICER said would be acceptable in a July report. bluebird has opted to launch it at a cost of $2.8 million, which compares to the $1.7
52 
Let's personalize your content